P102 Safety evaluation from an ongoing randomized, double-blind, multiple-ascending dose phase Ib study of enpatoran versus placebo in patients with active systemic or cutaneous lupus erythematosus (SLE/CLE)

• Torsten Witte,
• Sanjeev Roy,
• Joerg Wenzel,
• Nadezda Abramova,
• Dominika Weinelt,
• Deborah Denis

Affiliations

Torsten Witte

1 Rheumatology and Immunology, Hannover Medical School, Hannover, Germany

Sanjeev Roy

7Merck, Aubonne, Switzerland, a division of Merck KGaA, Darmstadt, Germany

Joerg Wenzel

1Dept. of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany

Nadezda Abramova

2Global Patient Safety, Merck Healthcare KGaA, Darmstadt, Germany

Dominika Weinelt

2Global Patient Safety, Merck Healthcare KGaA, Darmstadt, Germany

Deborah Denis

3Global Clinical Development, EMD Serono Research and Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA